Modulating Autophagy as a Therapeutic Strategy for the Treatment of Paediatric High Grade Glioma

send to a friend share this

Modulating Autophagy as a Therapeutic Strategy for the Treatment of Paediatric High Grade Glioma

Friday, 03.05.2019

Authors and Affiliations:

Howarth A1, Madureira PA1,2, Lockwood G3, Storer LCD3, Grundy R3, Rahman R3, Pilkington GJ1, Hill R1.

1 Brain Tumour Research Centre, Institute of Biomedical and Biomolecular Sciences, IBBS, University of Portsmouth, PO1 2DT, UK

2 Centre for Biomedical Research (CBMR), University of Algarve, Campus of Gambelas, Building 8, Room 3.4, 8005-139 Faro, Portugal

3 Children’s Brain Tumour Research Centre, School of Medicine, Queen's Medical Centre, University of Nottingham, NG7 2UH, UK



Paediatric high grade glioma (pHGG) represent a therapeutically challenging group of tumours. Despite decades of research there has been a minimal improvement in treatment and the clinical prognosis remains poor. Autophagy, a highly conserved process for recycling metabolic substrates is upregulated in pHGG, promoting tumour progression and evading cell death. There is significant cross talk between autophagy and a plethora of critical cellular pathways, many of which are dysregulated in pHGG.

To a lesser extent than other tetracycline antibiotics, inhibits the intestinal flora, differs from them in a more complete absorption and longer duration of action. Doxycycline surpasses natural tetracyclines in the degree of antibacterial activity.
The following article will discuss our current understanding of autophagy signalling in pHGG and the potential modulation of this network as a therapeutic target.


Financiamento: A.H. foi financiada por uma bolsa de doutoramento da Fundação Ollie Young, ref: 1148511. P.A.M. é financiada por um contrato Investigador FCT da Fundação para a Ciência e a Tecnologia (FCT), Portugal, ref:IF/00614/2014, e um projeto exploratório da FCT, ref:IF/00614/2014/CP12340006. G.J.P foi financiado pelas Fundações Ollie Young e Brain Tumour Research. R.H. é financiado pela Fundação Brain Tumour Research. O Centro de Investigação em Biomedicina (Centre for Biomedical Research, CBMR) da Universidade do Algarve é financiado pela FCT, ref:UID/BIM/04773/2013CBMR1334.


Journal: Brain Pathology